Swiss Bio-Pharma Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 14 Year, 5 Months
- Last Filing with ROC 31 Mar 2024
- Revenue Growth %
- Profit Growth -249.93%
- Ebitda -37.50%
- Net Worth -17.95%
- Total Assets 57.26%
About Swiss Bio-Pharma
Swiss Bio-Pharma Private Limited (SBPL) is a Private Limited Indian Non-Government Company incorporated in India on 01 September 2010 and has a history of 14 years and five months. Its registered office is in Ahmedabad, Gujarat, India.
The Company is engaged in the Chemicals Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Vikrambhai Shah and Naishadh Shah serve as directors at the Company.
Company Details
-
Location
Ahmedabad, Gujarat, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
Social Media
Corporate Identity Details
-
CIN/LLPIN
U24230GJ2010PTC062185
-
Company No.
062185
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
01 Sep 2010
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Ahmedabad
Industry
Who are the key members and board of directors at Swiss Bio-Pharma?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Naishadh Shah
|
Director | 01-Sep-2010 | Current |
|
Vikrambhai Shah
|
Director | 01-Sep-2010 | Current |
Financial Performance of Swiss Bio-Pharma.
Swiss Bio-Pharma Private Limited, for the financial year ended 2022, experienced no change in revenue, with a 0% increase. The company also saw a substantial fall in profitability, with a 249.93% decrease in profit. The company's net worth observed a substantial decline by a decrease of 17.95%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Swiss Bio-Pharma?
In 2017, Swiss Bio-Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Swiss Nutraceuticals Private LimitedVikrambhai Shah and Naishadh Shah are mutual person
-
Swiss Exports Private Limited
Vikrambhai Shah and Naishadh Shah are mutual person
-
Swiss Parenterals Limited
Naishadh Shah is a mutual person
-
Healthbest Private LimitedVikrambhai Shah and Naishadh Shah are mutual person
-
Biorx Pharma Labs LlpVikrambhai Shah and Naishadh Shah are mutual person
-
Syncorp Ventures Llp
Vikrambhai Shah and Naishadh Shah are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Swiss Bio-Pharma?
Unlock and access historical data on people associated with Swiss Bio-Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Swiss Bio-Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Swiss Bio-Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
